GRITSTONE BIO INC (GRTS)
US39868T1051 - Common Stock
GRTS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of GRTS have multiple concerns. GRTS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
GRTS had negative earnings in the past year.
In the past year GRTS has reported a negative cash flow from operations.
In the past 5 years GRTS always reported negative net income.
GRTS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GRTS has a Return On Assets of -77.90%. This is in the lower half of the industry: GRTS underperforms 70.21% of its industry peers.
GRTS has a Return On Equity of -267.09%. This is in the lower half of the industry: GRTS underperforms 72.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.9% | ||
| ROE | -267.09% | ||
| ROIC | N/A |
ROA(3y)-51.54%
ROA(5y)-50.67%
ROE(3y)-123.97%
ROE(5y)-101.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GRTS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GRTS has more shares outstanding
GRTS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GRTS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.90, we must say that GRTS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GRTS (-6.90) is worse than 69.18% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that GRTS is somewhat dependend on debt financing.
The Debt to Equity ratio of GRTS (0.77) is worse than 75.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.9 |
ROIC/WACCN/A
WACC8.59%
2.3 Liquidity
GRTS has a Current Ratio of 3.20. This indicates that GRTS is financially healthy and has no problem in meeting its short term obligations.
GRTS has a worse Current ratio (3.20) than 64.04% of its industry peers.
GRTS has a Quick Ratio of 3.20. This indicates that GRTS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.20, GRTS is not doing good in the industry: 62.84% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.77% over the past year.
Looking at the last year, GRTS shows a very negative growth in Revenue. The Revenue has decreased by -17.99% in the last year.
GRTS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.87% yearly.
EPS 1Y (TTM)9.77%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q13.33%
Revenue 1Y (TTM)-17.99%
Revenue growth 3Y59.34%
Revenue growth 5Y68.87%
Revenue growth Q2Q143.73%
3.2 Future
Based on estimates for the next years, GRTS will show a very strong growth in Earnings Per Share. The EPS will grow by 23.01% on average per year.
Based on estimates for the next years, GRTS will show a very strong growth in Revenue. The Revenue will grow by 93.79% on average per year.
EPS Next Y13%
EPS Next 2Y8.25%
EPS Next 3Y-2.67%
EPS Next 5Y23.01%
Revenue Next Year25.69%
Revenue Next 2Y106.44%
Revenue Next 3Y-27.03%
Revenue Next 5Y93.79%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GRTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GRTS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GRTS's earnings are expected to decrease with -2.67% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.25%
EPS Next 3Y-2.67%
5. Dividend
5.1 Amount
No dividends for GRTS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GRITSTONE BIO INC
NASDAQ:GRTS (4/26/2024, 7:00:02 PM)
After market: 0.82 +0.01 (+0.81%)0.8134
+0.05 (+6.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap86.16M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.9% | ||
| ROE | -267.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)9.77%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y13%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-17.99%
Revenue growth 3Y59.34%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y